Immunohistochemistry of DNA mismatch repair enzyme MSH2 is not correlated with prognostic data from endometrial carcinomas

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4833-4837

  Schröer, Andreas ^a   Köster, Frank ^a   Fischer, Dorothea ^a   Dubitscher, Ralph Martin ^b   Woll Hermann, Astrid ^b   Diedrich, Klaus ^a   Friedrich, Michael ^c   Salehin, Darius ^c  

^a UNIVERSITY OF LÜBECK   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c HELIOS Clinic Krefeld   (Germany)

Author keywords

DNA mismatch repair; Endometrial cancer; Immunohistochemistry; MSH2

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN MSH2;

ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENETIC CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROGNOSIS;

APOPTOSIS; DNA MISMATCH REPAIR; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MUTS HOMOLOG 2 PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 75149133712     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, Jarvinen H, Powell SM, Jen J, Hamilton SR et al: Clues to the pathogenesis of familial colorectal cancer. Science 260: 812-816, 1993.
2. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M and Kolodner R: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75: 1027-1038, 1993.
3. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomaki P, Sistonen P, Aaltonen LA, Nystrom-Lahti M et al: Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75: 1215-1225, 1993.
4. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomaki P, Mecklin JP and Jarvinen HJ: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81: 214-218, 1999.
5. Lynch HT, Casey MJ, Shaw TG and Lynch JF: Hereditary factors in gynecologic cancer. Oncologist 3: 319-338, 1998.
6. Watson P, Riley B: The tumor spectrum in the lynch syndrome. Fam Cancer 4: 245-248, 2005.
7. Garg K, Leitao MM Jr, Kauff ND, Hansen J, Kosarin K, Shia J and Soslow RA: Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol 33: 925-933, 2009.
8. Adem C, Soderberg CL, Cunningham JM, Reynolds C, Sebo TJ, Thibodeau SN, Hartmann LC and Jenkins RB: Microsatellite instability in hereditary and sporadic breast cancers. Int J Cancer 107:580-582, 2003.
9. Ciavattini A, Piccioni M, Tranquilli AL, Filosa A, Pieramici T and Goteri G: Immunohistochemical expression of DNA mismatch repair (MMR) system proteins (hMLH1, hMSH2) in cervical preinvasive and invasive lesions. Pathol Res Pract 201:21-25, 2005.
10. Friedrich M, Meyberg R, Villena-Heinsen C, Woll-Hermann A, Reitnauer K, Schmidt W, Tilgen W and Reichrath J: Immunohistochemical analysis of DNA mismatch-repair enzyme hMSH-2 and Ki-67 in breast carcinomas. Anticancer Res 19:3349-3353, 1999.
11. Friedrich M, Villena-Heinsen C, Meyberg R, Woll-Hermann A, Reitnauer K, Schmidt W, Tilgen W and Reichrath J: Immunohistochemical analysis of DNA 'mismatch-repair' enzyme human mut-S-homologon-2 in ovarian carcinomas. Histochem J 31: 717-722, 1999.
12. Koster F, Schroer A, Fischer D, Greweldinger T, Diedrich K and Friedrich M: Correlation of DNA mismatch repair protein hMSH2 immunohistochemistry with p53 and apoptosis in cervical carcinoma. Anticancer Res 27: 63-68, 2007.
13. Koster F, Schroer A, Fischer D, Horn AK, Diedrich K and Friedrich M: Immunohistochemistry of proteins for DNA mismatch repair in correlation to prognostic factors of mammarian cancer. Oncol Rep 17: 1223-1227, 2007.
14. Mylona E, Zarogiannos A, Nomikos A, Giannopoulou I, Nikolaou I, Zervas A and Nakopoulou L: Prognostic value of microsatellite instability determined by immunohistochemical staining of HMSH2 and HMSH6 in urothelial carcinoma of the bladder. APMIS 116: 59-65, 2008.
15. Cooper WA, Kohonen-Corish MR, Chan C, Kwun SY, McCaughan B, Kennedy C, Sutherland RL and Lee CS: Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small cell lung cancer and precursor lesions. Histopathology 52: 613-622, 2008.
16. Erdamar S, Ucaryilmaz E, Demir G, Karahasanoglu T, Dogusoy G, Dirican A and Goksel S: Importance of mutL homologue MLH1 and mutS homologue MSH2 expression in Turkish patients with sporadic colorectal cancer. World J Gastroenterol 13: 4437-4444, 2007.
17. Chintamani, Jha BP, Bhandari V, Bansal A, Saxena S and Bhatnagar D: The expression of mismatched repair genes and their correlation with clinicopathological parameters and response to neo-adjuvant chemotherapy in breast cancer. Int Semin Surg Oncol 4: 5-12, 2007.
18. Christmann M and Kaina B: Nuclear translocation of mismatch repair proteins MSH2 and MSH6 as a response of cells to alkylating agents. J Biol Chem 275: 36256-36262, 2000.
19. Claij N and te Riele H: Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells. Oncogene 23: 260-266, 2004.
20. Clodfelter JE, M BG and Drotschmann K: MSH2 missense mutations alter cisplatin cytotoxicity and promote cisplatin-induced genome instability. Nucleic Acids Res 33: 3323-3330, 2005.
21. Drummond JT, Anthoney A, Brown R and Modrich P: Cisplatin and adriamycin resistance are associated with mutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 271: 19645-19648, 1996.
22. Fedier A, Schwarz VA, Walt H, Carpini RD, Haller U and Fink D: Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer 93: 571-576, 2001.
23. Runger TM, Emmert S, Schadendorf D, Diem C, Epe B and Hellfritsch D: Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. J Invest Dermatol 114: 34-39, 2000.
24. Friedrich M, Villena-Heinsen C, Reitnauer K, Schmidt W, Tilgen W and Reichrath J: Malignancies of the uterine corpus and immunoreactivity score of the DNA "mismatch-repair" enzyme human mut-S-homologo-2. J Histochem Cytochem 47: 113-118, 1999.
25. Friedrich M: Analysis of the DNA "mismatch-repair" enzyme human mut-S-homologon-2 in endometrial cancer on protein and RNA level. Eur J Gynaecol Oncol 21: 273-277, 2000.
26. Cohn DE, Frankel WL, Resnick KE, Zanagnolo VL, Copeland LJ, Hampel H, Kelbick N, Morrison CD and Fowler JM: Improved survival with an intact DNA mismatch repair system in endometrial cancer. Obstet Gynecol 108: 1208-1215, 2006.
27. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (1RS) for immunohisto-chemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987.
28. Peiro G, Diebold J, Mayr D, Baretton GB, Kimmig R, Schmidt M and Lohrs U: Prognostic relevance of hMLH1, hMSH2, and BAX protein expression in endometrial carcinoma. Mod Pathol 14: 777-783, 2001.
29. Giarnieri E, Mancini R, Pisani T, Alderisio M and Vecchione A: Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix. Clin Cancer Res 6: 3600-3606, 2000.
30. Athanassiadou P, Athanassiades P, Grapsa D, Gonidi M, Athanassiadou AM, Stamati PN and Patsouris E: The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: A prospective immunocytochemical study. Int J Gynecol Cancer 17: 697-704, 2007.
31. Kalogiannidis I, Bobos M, Papanikolaou A, Makedos A, Amplianitis I, Vergote I, Nenopoulou E and Makedos G: Immunohistochemical bcl-2 expression, p53 overexpression, PR and ER status in endometrial carcinoma and survival outcomes. Eur J Gynaecol Oncol 29: 19-25, 2008.
32. Scherer SJ, Seib T, Seitz G, Dooley S and Welter C: Isolation and characterization of the human mismatch repair gene hMSH2 promoter region. Hum Genet 97: 114-116, 1996.
33. Scherer SJ, Welter C, Zang KD and Dooley S: Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2. Biochem Biophys Res Commun 221: 722-728, 1996.
34. Labat-Moleur F, Guillermet C, Lorimier P, Robert C, Lantuejoul S, Brambilla E and Negoescu A: TUNEL apoptotic cell detection in tissue sections: Critical evaluation and improvement. J Histochem Cytochem 46: 327-334, 1998.